Clinical Trial Update: Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants [Phase 2]

View source ↗

Summary

Phase 2 window-of-opportunity trial of defactinib in surgically resectable malignant pleural mesothelioma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Defactinib (defactinib)

Snippet

Sponsor: Verastem, Inc. | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: TERMINATED | Results posted: 2024-02-20